Articles tagged "Highly-sensitized"

2022 American Transplant Congress
Characterizing the Landscape of Cancer Risk Following HLA-Incompatible Living Donor Kidney Transplantation
J. D. Motter¹, K. Jackson¹, K. Yu², R. M. Pfeiffer², A. Massie¹, J. Garonzik-Wang³, D. Segev¹, E. A. Engels²
¹Johns Hopkins University, Baltimore, MD, ²National Cancer Institute, Bethesda, MD, ³University of Wisconsin-Madison, Madison, WI
*Purpose: Incompatible living donor kidney transplant recipients (ILDKTr) require desensitization to facilitate transplantation across donor-specific antibody (DSA); however, this substantial upfront immunosuppression may result in…
2022 American Transplant Congress
Long-Term Outcomes of Crossmatch Positive Simultaneous Liver Kidney Transplants in the United States
S. Riad¹, E. Aby¹, S. Jackson², P. Nguyen³, N. Lim¹, J. Lake¹
¹Medicine, University of Minnesota, Minneapolis, MN, ²Mhealth-Fairview, Minneapolis, MN, ³Surgery, University of Minnesota, Minneapolis, MN
*Purpose: The long-term results of crossmatch positive (XM+) simultaneous liver-kidney (SLK) transplants are conflicting. We examined the association between crossmatch (XM) status and SLK outcomes…
2022 American Transplant Congress
Outcomes of Hlai Kidney Transplants in Patients with Cpra 100% After Desensitization
A. A. Vo¹, J. Tang¹, S. Williamson¹, C. Meyers¹, E. Huang¹, X. Zhang², M. Haas³, A. Peng¹, R. Najjar¹, S. Supreet¹, N. Ammerman¹, K. Lim¹, M. Gillespie¹, N. Badash¹, S. Jordan¹
¹Comprehensive Transplant Center, Cedars Sinai Medical Ctr, Los Angeles, CA, ²HLA Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA, ³Pathology, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: The KAS implementation was aimed at increasing access to kidney transplantation in highly HLA sensitized (HS) patients. However, combining desensitization (DES) + KAS could…
2022 American Transplant Congress
Successful Outcome of Highly Sensitized Patients After Heart Transplantation Under RATG Regimen
G. Esmailian, T. Singer-Englar, J. Patel, M. Kittleson, S. Kim, N. Patel, D. Chang, E. Kransdorf, F. Esmailian, J. A. Kobashigawa
Cedars-Sinai Smidt Heart Institute, Los Angeles, CA
*Purpose: Highly sensitized patients (panel reactive antibody [PRA] ≥50%) are known to be at risk for poor outcome after heart transplantation (HTx). In our program,…
2021 American Transplant Congress
Kidney Transplantation in Very Highly-Sensitized Patients with Maastricht Type III Non-heart-Beating Donors
F. Villanego¹, A. Mazuecos¹, L. Vigara¹, V. Lopez², G. Bernal³, A. Rodriguez-Benot⁴, M. de Gracia⁵, P. Castro⁶, A. Alvarez⁶
¹Department of Nephrology, Hospital Puerta del Mar, Cadiz, Spain, ²Department of Nephrology, Hospital Carlos Haya, Malaga, Spain, ³Department of Nephrology, Hospital Virgen del Rocio, Sevilla, Spain, ⁴Department of Nephrology, Hospital Reina Sofia, Cordoba, Spain, ⁵Department of Nephrology, Hospital Virgen de las Nieves, Granada, Spain, ⁶Andalusian Transplant Coordination, Sevilla, Spain
*Purpose: In 2012, a kidney transplant (KT) program for very highly-sensitized (VHS) patients (PRA ≥ 95%) based on virtual crossmatch began in Andalusia (Spanish region).…
2021 American Transplant Congress
Desensitization Using Costimulatory Blockade and Bortezomib to Prevent DSA Formation and Rejection in Reconstructive Transplantation
B. Oh¹, F. Messner², Y. Guo¹, G. Brandacher¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Department of Visceral, Transplant and Thoracic Surgery, University of Innsbruck, Innsbruck, Austria
*Purpose: Sensitization in form of donor-specific antibodies (DSA) and subsequent antibody-mediated rejection constitute some of the greatest risk factors for allograft rejection and long-term graft…
2021 American Transplant Congress
Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)
A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Sethi¹, S. Williamson¹, C. Myers¹, K. Lim¹, M. Gillespie¹, S. Jordan¹
¹Kidney Transplant, Cedars Sinai Medical Ctr, Los Angeles, CA, ²Transplant Immunology Laboratory, Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: IL-6 is a critical cytokine for plasma cell IgG production. Clazakizumab (CSL Behring LLC) is a humanized monoclonal aimed at the cytokine IL-6. Here…
2021 American Transplant Congress
Sensitized Lung Candidates Experience Reduced Access to Donor Organs
K. Lindblad¹, R. Goff², D. Stewart²
¹UNOS, Richmond, VA, ²UNOS, Richmnd, VA
*Purpose: Most studies of sensitization in transplant candidates have focused on kidney candidates, and unacceptable antigens (UAs) for non-kidney candidates are believed to be underreported.…
2021 American Transplant Congress
HLA Haplotype Frequency and Racial Disparities in Access to Transplant Among Highly Sensitized Kidney Transplant Candidates
L. Gragert¹, M. Kadatz², D. Chang², H. Gebel³, D. Stewart⁴, E. Kransdorf⁵, S. Brar², S. Vaishnav², J. Gill², J. Lan²
¹Tulane University, New Orleans, LA, ²University of British Columbia, Vancouver, BC, Canada, ³Emory University, Atlanta, GA, ⁴UNOS, Richmond, VA, ⁵Cedars-Sinai, Beverly Hills, CA, Canada
*Purpose: Despite implementation of the Kidney Allocation System (KAS) which prioritizes sensitized patients, sensitized Black individuals are less likely to receive a transplant than non-Black…
2021 American Transplant Congress
Safety and Tolerability of Tacrolimus Extended-Release (astagraf Xl) in Hla Sensitized Kidney Transplant Recipients: A Single Center Experience
A. A. Vo, N. Ammerman, E. Huang, A. Peng, R. Najjar, S. Sethi, K. Lim, M. Gillespie, S. C. Jordan
Cedars Sinai Medical Ctr, Los Angeles, CA
*Purpose: Pill burden is a limitation in kidney transplant. Tacrolimus extended-release (Astagraf XL) is a once daily formulation approved for kidney transplantation. Increased compliance could…